1️⃣ J&J walked away from a CAR-T franchise it once sized at $5B
Johnson & Johnson discontinued its CD20 mono CAR-T and CD19/CD20 bi-CAR-T programs in large B-cell lymphoma, citing portfolio priorities and the changing treatment landscape.
💡 Why it matters
This is a clean reset of cell therapy ambition. J&J kept Carvykti, but dropped the lymphoma expansion before Phase 3 despite strong early response data.
☕ Coffee talk
If 75% to 80% complete response was not enough to keep this alive, what is J&J really afraid of in lymphoma?
2️⃣ FDA pushed back on AstraZeneca’s ctDNA switch strategy
FDA advisers voted 6-3 that camizestrant had not shown clinically meaningful benefit for switching HR+/HER2- metastatic breast cancer patients before radiographic progression.
💡 Why it matters
The issue is not just one oral SERD. The agency is questioning whether biomarker-triggered early switching improves outcomes enough to change treatment sequence.
☕ Coffee talk
How many ctDNA-guided trials just got harder to sell without an overall survival answer?
3️⃣ BeOne bought an option, not conviction
BeOne agreed to pay Huahui Health $20M upfront for a global option on HH160, a preclinical PD-1/CTLA-4/VEGF-A trispecific, with up to $2.0B in later payments.
💡 Why it matters
The structure says plenty. Big headline value, tiny initial cheque, and a China-originated IO asset that still has to prove it is more than target stacking.
☕ Coffee talk
At $20M down, is this a serious global oncology bet or just cheap access to the next China IO wave?